Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease.

ABSTRACT:

Objective

Our aim was to investigate the effectiveness and tolerability of antifibrotics in a real-world cohort of patients with rheumatoid arthritis-associated interstitial lung diseases (RA-ILD).

Methods

In this retrospective cohort study, we identified RA-ILD patients initiating antifibrotics at Mass General Brigham Integrated Health Care System, a large multi-hospital healthcare system in Boston, MA, USA. We used electronic query to identify all patients with at least 2 RA diagnosis codes and a prescription for either nintedanib or pirfenidone (2014-2023). All analyzed patients met 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA and had definite RA-ILD according to Bongartz criteria. Data regarding p

SUBMITTER: Juge PA 

PROVIDER: S-EPMC10841613 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature